AnaptysBio (ANAB)
NASDAQ:ANAB
Want to see ANAB full AI Analyst Report?
ANAB Stock Chart & Stats
$67.89
-$0.23(-1.55%)
At close: 4:00 PM EST
$67.89
-$0.23(-1.55%)
Day’s Range― - ―
52-Week Range$17.11 - $73.30
Previous CloseN/A
Volume154.73K
Average Volume (3M)640.71K
Market Cap
$1.95B
Enterprise Value$2.00B
Total Cash (Recent Filing)$311.64M
Total Debt (Recent Filing)$290.64M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
May 07, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.58
Shares Outstanding28,748,255
10 Day Avg. Volume504,456
30 Day Avg. Volume640,708
Financial Highlights & Ratios
PEG Ratio1.12
Price to Book (P/B)36.21
Price to Sales (P/S)5.74
P/FCF Ratio68.70
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue8.54
Enterprise Value/Gross Profit8.63
Enterprise Value/Ebitda30.03
Forecast
1Y Price Target
$83.22Price Target Upside22.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.94
Revenue Forecast (FY)$111.27M
Bulls Say, Bears Say
Bulls Say
Clinical Development CatalystsUpcoming topline phase 1b results and multiple near-term program readouts for the lead antibody could drive stock gains if they show meaningful clinical benefit in celiac disease and related indications.
Corporate RestructuringPlanned separation into a royalty company and a biopharma company could unlock value by letting the royalty arm focus on steady income while the biopharma arm advances drug development.
Differentiated Therapeutic MechanismLead program's dual-targeting approach addresses immune pathways not reached by single-target therapies, potentially improving efficacy and commercial prospects if clinical signals hold up.
Bears Say
Class-level Clinical RiskDiscontinuation of a peer's similar program highlights class-level safety or efficacy concerns and raises uncertainty about regulatory and commercial prospects for comparable therapies.
Legal Risk To Royalty RevenueAn ongoing legal dispute with a partner creates meaningful downside risk to expected royalty revenues while breach claims remain unresolved.
Tax Implications For ShareholdersDistribution of new shares as a taxable transaction may create a tax burden for shareholders and could reduce demand for the spun-off equity.
AnaptysBio News
ANAB FAQ
What was AnaptysBio’s price range in the past 12 months?
AnaptysBio lowest stock price was $17.11 and its highest was $73.30 in the past 12 months.
What is AnaptysBio’s market cap?
AnaptysBio’s market cap is $1.95B.
When is AnaptysBio’s upcoming earnings report date?
AnaptysBio’s upcoming earnings report date is May 07, 2026 which is in 21 days.
How were AnaptysBio’s earnings last quarter?
AnaptysBio released its earnings results on Mar 03, 2026. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.863 by $0.717.
Is AnaptysBio overvalued?
According to Wall Street analysts AnaptysBio’s price is currently Undervalued.
Does AnaptysBio pay dividends?
AnaptysBio does not currently pay dividends.
What is AnaptysBio’s EPS estimate?
AnaptysBio’s EPS estimate is -0.96.
How many shares outstanding does AnaptysBio have?
AnaptysBio has 28,748,255 shares outstanding.
What happened to AnaptysBio’s price movement after its last earnings report?
AnaptysBio reported an EPS of $1.58 in its last earnings report, beating expectations of $0.863. Following the earnings report the stock price went up 14.613%.
Which hedge fund is a major shareholder of AnaptysBio?
Currently, no hedge funds are holding shares in ANAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AnaptysBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$83.22 (22.58% Upside)
$83.22 (22.58% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 17.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.9%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
275.08%
12-Months-Change
Fundamentals
Return on Equity
1813.84%
Trailing 12-Months
Asset Growth
-24.69%
Trailing 12-Months
Company Description
AnaptysBio
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB Stock 12 Month Forecast
Average Price Target
$83.22
▲(22.58% Upside)
Technical Analysis
Meiragtx Holdings
―
Keros Therapeutics
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Terns Pharmaceuticals
―
Ownership Overview
Currently, No data available
---